3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
3
Breast Neoplasms
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Breast Neoplasms, Male
2
Vulvar Neoplasms
1
Vipoma
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Parathyroid Neoplasms
1
Interventions
Paclitaxel
68
Carboplatin
64
pembrolizumab
32
Cyclophosphamide
32
Bevacizumab
27
liposomal doxorubicin
24
Cisplatin
24
Topotecan
21
Gemcitabine
21
olaparib
18
fludarabine
17
Taxes
16
Docetaxel
15
Nivolumab
14
Doxorubicin
14
niraparib
13
veliparib
12
Albumin-Bound Paclitaxel
11
aldesleukin
9
Filgrastim
9
fludarabine phosphate
8
durvalumab
8
Oxaliplatin
8
Fluorouracil
8
Drug Therapy
8
sargramostim
7
Peripheral Blood Stem Cell Transplantation
7
Magnetic Resonance Spectroscopy
7
Leucovorin
7
talazoparib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Ovarian Neoplasms
×
Interleukin-12
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled